VB4-845: A conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 2, 2008, Pages 176-186

  Biggers, K ^a   Scheinfeld, N ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; IMMUNOTOXIN; METHOTREXATE; PACLITAXEL; PSEUDOMONAS EXOTOXIN; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VB 4845;

BLADDER CANCER; BREAST ADENOCARCINOMA; CLINICAL TRIAL; COLON ADENOCARCINOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HEAD AND NECK CANCER; HUMAN; INJECTION SITE PAIN; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATENT; REVIEW; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTOXINS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER NEOPLASMS;

PSEUDOMONAS EXOTOXIN;

EID: 41849099638     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 313866 Ligand receives FDA approval for ONTAK for treatment of patients with cutaneous T-cell lymphoma. Ligand Pharmaceuticals Inc PRESS RELEASE 1999 February 05
2. 465618 VBI licenses University of Zurich immunotoxin. Viventia Biotech Inc PRESS RELEASE 2002 October 01
3. 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Borjesson PKE, Postema EJ, Roos JC, Colnot DR, Marres HAM, van-Schie MH, Stehle G, de-Bree R, Snow GB, Oyen WJG, van-Dongen GAMS CLIN CANCER RES 2003 9 10 2 3961s-3972s
4. 523128 Erbitux receives US approval for metastatic colorectal cancer. ImClone Systems Inc PRESS RELEASE 2004 February 12
5. 533749 Pierre Fabre partners with BMS to develop Javlor for cancer. Bristol-Myers Squibb Co, Pierre Fabre SA PRESS RELEASE 2004 April 20
6. 567224 Viventia's head and neck cancer drug shows phase I promise. Viventia Biotech Inc PRESS RELEASE 2004 October 27
7. 583426 Viventia reaches antibody milestone; Proxinium gets US orphan status. Viventia Biotech Inc PRESS RELEASE 2005 February 03
8. 583852 Effective tumor targeting: Strategies for the delivery of armed antibodies. MacDonald GC, Glover N CURR OPIN DRUG DISCOV DEVEL 2005 8 2 177-183
9. 592034 Technology evaluation: Nimotuzumab, The Center of Molecular Immunology/YM BioSciences/Oncoscience. Spicer J CURR OPIN MOL THER 2005 7 2 182-191
10. 592144 Viventia's Proxinium clears tumors in phase I trial. Viventia Biotech Inc PRESS RELEASE 2005 March 29
11. 593666 A preclinical profile of Proxinium, a recombinant immunotoxin for targeting head and neck cancer. Brown J, Cizeau J, Bosc D, Entwistle J, Glover N, MacDonald GC PROC AM ASSOC CANCER RES 2005 46 Abs 686
12. 601540 A phase I open-label study to evaluate safety, tolerability and pharmacokinetic (PK) profile of VB4-845, an anti-EpCAM immunotoxin, in subjects with SCCHN. Quenneville J, Fitsialos D, Rasamoelisolo M, Cross M, Glover N, MacDonald G PROC AM SOC CLIN ONCOL 2005 24 Abs 5539
13. 604998 Viventia's Proxinium gets EU Orphan status for head and neck cancer. Viventia Biotech Inc PRESS RELEASE 2005 June 01
14. 614736 Wyeth's Mylotarg approved in Japan for AML. Wyeth PRESS RELEASE 2005 July 27
15. 627368 Viventia's Proxinium renamed Vicinium for bladder cancer. Viventia Biotech Inc PRESS RELEASE 2005 October 06
16. 633960 Viventia's Proxinium designated US Fast Track for head and neck cancer. Viventia Biotech Inc PRESS RELEASE 2005 November 10
17. 634542 Viventia Biotech reports third quarter 2005 results. Viventia Biotech Inc PRESS RELEASE 2005 November 14
18. 649551 Fresenius receives orphan drug designation for antibody removab to treat patients with ovarian cancer. Fresenius AG PRESS RELEASE 2004 March 19
19. 662534 A phase I study of VB4-845 in patients with advanced, recurrent head and neck cancer on a weekly dosing scheme. Fitsialos D, Quenneville J, Rasamoelisolo M, Cross M, Glover N, MacDonald G J CLIN ONCOL 2005 23 16 Abs 5569
20. 663136 NCT00272181: A phase II, open-label study to evaluate the safety, tolerability, and pharmacokinetic profile of Proxinium in patients with recurrent squamous cell carcinoma of the head and neck who have received at least one prior anti-cancer treatment regimen for recurrent disease. Viventia Biotech Inc WWW.CLINICALTRIALS.GOV 2006 January 03
21. 670969 Phase I/II study of Vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results. Fitsialos D PROC AM SOC CLIN ONCOL 2006 25 Abs 4580
22. 676822 The biology of the 17-1A antigen (Ep-CAM). Balzar M, Winter MJ, de Boer CJ, Litvinov SV J MOL MED 1999 77 10 699-712
23. 748767 Micromet and Serono amend adecatumumab agreement. Micromet Inc PRESS RELEASE 2006 December 05
24. 756933 NCT00412776: Study of Proxinium plus best supportive care versus best supportive care for patients with advanced head and neck cancer. Viventia Biotech Inc CLINICALTRIALS.GOV 2008 February 08
25. 766105 Viventia Biotech provides update on cancer antibody clinical development programs. Viventia Biotech Inc PRESS RELEASE 2007 February 14
26. 780234 Viventia begins Vicinium phase II trial for bladder cancer. Viventia Biotech Inc PRESS RELEASE 2007 April 03
27. 784577 Evaluation of the immunotoxin, Proxinium in combination with chemotherapy and radiotherapy. Brown JG, Rasamoelisolo M, Cizeau J, Bosc D, Entwistle J, Glover N, MacDonald GC AM ASSOC CANCER RES ANN MEET 2007 98 Abs 4103
28. 798946 Viventia Biotech reports final Vicinium phase I/II bladder cancer data at the American Urological Association Annual Meeting. Viventia Biotech Inc PRESS RELEASE 2007 May 24
29. 835237 A phase I/II study of Vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I final results. Fitsialos D, Seitz S, Wiecek E, Rasamoelisolo M, Entwistle J, Jewett M, MacDonald GC, Glover N J CLIN ONCOL 2006 24 18S Abs 4580
30. 848835 Surveillance, epidemiology and end results program: Survival in cancers of the head and neck. National Cancer Institute MONOGR NATL CANCER INST 2004 December 31
31. 848844 Cancer Research UK: Information on bladder cancer. Cancer Research UK COMPANY WORLD WIDE WEB SITE 2007 August 31
32. 848849 NCT00462488: Study of Vicinium for treating patients with non-invasive urothelial carcinoma in situ. Viventia Biotech Inc CLINICALTRIALS.GOV 2007 April 17
33. 848851 Product information: Proxinium. Viventia Biotech Inc COMPANY WORLD WIDE WEB SITE 2007 September 13
34. 848999 Molecular pathology of head and neck cancer. Crowe DL, Hacia JG, Hsieh CL, Sinha UK, Rice H HISTOL HISTOPATHOL 2002 17 3 909-914
35. 849002 Emerging drugs for head and neck cancer. Haddad R, Wirth L, Posner M EXPERT OPIN EMERG DRUGS 2006 11 3 461-467
36. 849007 Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P CA CANCER J CLIN 2005 55 2 74-108
37. 849010 Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC AM J PATHOL 2007 171 2 386-395
38. 849015 EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinomas of the bladder. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C J CLIN PATHOL 2008 61 3 307-310
39. 849016 Limited suitability of EpCAM for molecular staging of tumor borders in head and neck cancer. Andratschke M, Hagedorn H, Luebbers CW, Schmitt B, Lang S, Zeidler R, Wollenberg B ANTICANCER RES 2006 26 1A 153-158
40. 849017 A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Plückthun A, Stahel RA, Zangemeister-Wittke U CLIN CANCER RES 2003 9 7 2837-2848
41. 849019 Diphtheria toxin: Site and configuration of ADP-ribosylation of diphthamide in elongation factor 2. Oppenheimer NJ, Bodley JW J BIOL CHEM 1981 256 16 8579-8581
42. 849021 High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun A CANCER RES 1999 59 22 5758-5767
43. 853362 Product information: Vicinium. Viventia Biotech Inc COMPANY WORLD WIDE WEB SITE 2007 September 13
44. 853364 EpCAM expression in normal, non-pathological tissues. Schmelzer E, Reid LM FRONT BIOSCI 2008 13 3096-3100
45. 871828 Viventia Biotech to explore strategic alternatives - reports positive pivotal phase III interim efficacy data. Viventia Biotech Inc PRESS RELEASE 2008 January 29
46. 875209 Current clinical outcomes demand new treatment options for SCCHN. Lefebvre JL ANN ONCOL 2005 16 Suppl 6 7-12
47. 875232 Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M et al N ENGL J MED 2004 350 19 1937-1944
48. 875234 Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F et al N ENGL J MED 2004 350 19 1945-1952
49. 875428 Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U MOL CANCER THER 2007 6 11 3019-3027
50. 875439 Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model. Kosterink JG, McLaughlin PM, Lub-de Hooge MN, Hendrikse HH, van Zanten J, van Garderen E, Harmsen MC, de Leij LF J IMMUNOL 2007 179 2 1362-1368
51. 875449 Immunotoxins for targeted cancer therapy. Kreitman RJ AAPS J 2006 8 3 E532-E551
52. 875467 Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. Hughes OD, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Denley H, Rutherford R, Schubiger PA J CLIN ONCOL 2000 18 2 363-370
53. 875472 A phase I/II study of Vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I final results. Jones N, Jewett MAS, Cuthbert W, Rasamoelisolo M, Entwistle J, MacDonald G, Glover N ABS AM UROL ASSOC 2007 Abs 1575
54. 875474 Metastasis - an alternative hypothesis. Freireich EJ, Kurzrock R, Estrov Z CANCER 2005 103 8 1537-1539
55. 878993 Proxinium trials. Viventia Biotech Inc INTERNET SITE 2007 December 31
56. 878994 Vascular leak syndrome: A side effect of immunotherapy. Baluna R, Vitetta ES IMMUNOPHARMACOLOGY 1997 37 2-3 117-132
57. 879351 FDA grants accelerated approval of avastin in combination with paclitaxel chemotherapy for first-line treatment of advanced HER2-negative breast cancer. The Food and Drug Administration PRESS RELEASE 2008 February 21
58. 880144 State-of-the-art management of locally advanced head and neck cancer. Seiwert TY, Cohen EEW BR J CANCER 2005 52 8 1341-1348
59. 880151 Epidermal growth factor receptor biology in head and neck cancer. Kalyankrishna S, Grandis JR. J CLIN ONCOL 2006 24 17 2666-2672
60. 880152 Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Pignon JP, Bourhis J, Domenge C, Designé L LANCET 2000 355 9208 949-955
61. 881335 Expanding role of the medical oncologist in the management of head and neck cancer. Choong N, Vokes E CA CANCER J CLIN 2008 58 1 32-53
62. 881553 Focus on head and neck cancer. Mao L, Hong WK, Papadimitrakopoulou VA CANCER CELL 2004 5 4 311-316
63. 881556 The next generation biopharma leader full year 2007 results: UCB. UCB SA COMPANY PRESENTATION 2008 February 29
64. 881558 Perineural spread in head and neck malignancies. Ojiri H RADIAT MED 2006 24 1 1-8
65. 881623 Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Huang GJ, Stein JP CURR OPIN UROL 2007 17 5 369-375